» Articles » PMID: 18007144

Identification of an Intronic Single Nucleotide Polymorphism Leading to Allele Dropout During Validation of a CDH1 Sequencing Assay: Implications for Designing Polymerase Chain Reaction-based Assays

Overview
Journal Genet Med
Publisher Elsevier
Specialty Genetics
Date 2007 Nov 17
PMID 18007144
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The CDH1 gene encodes the cell adhesion protein E-cadherin, and CDH1 germline mutations are associated with hereditary diffuse gastric cancer. Identification of individuals at high risk of developing diffuse gastric cancer affords the opportunity for endoscopic screening or elective prophylactic gastrectomy. We set out to develop a CDH1 sequencing assay for clinical use.

Methods: All exons of the CDH1 gene were amplified and sequenced with published and modified primers.

Results: While validating the assay, we encountered a case in which a single nucleotide polymorphism located in intron 15 led to allele dropout and therefore to a false-negative result. The polymorphism leading to allele dropout was located within a primer-binding sequence, five bases away from the 3' end of the primer. A frameshift mutation in exon 15 was detected by an alternative primer that binds away from the polymorphic site. A search of the University of California Santa Cruz single nucleotide polymorphism database revealed other polymorphisms located within primer-binding sites. A total of 12 primers in nine primer sets were modified to minimize allele dropout risk.

Conclusion: The approach of designing primers to avoid known single nucleotide polymorphisms can be generalized to the design of any polymerase chain reaction-based assay and should be employed whenever possible.

Citing Articles

Identification and characterization of TP53 gene Allele Dropout in Li-Fraumeni syndrome and Oral cancer cohorts.

Haque M, Kowtal P, Sarin R Sci Rep. 2018; 8(1):11705.

PMID: 30076369 PMC: 6076284. DOI: 10.1038/s41598-018-30238-7.


Multi-ethnic SULT1A1 copy number profiling with multiplex ligation-dependent probe amplification.

Vijzelaar R, Botton M, Stolk L, Martis S, Desnick R, Scott S Pharmacogenomics. 2018; 19(9):761-770.

PMID: 29790428 PMC: 6021911. DOI: 10.2217/pgs-2018-0047.


Concordance between Research Sequencing and Clinical Pharmacogenetic Genotyping in the eMERGE-PGx Study.

Rasmussen-Torvik L, Almoguera B, Doheny K, Freimuth R, Gordon A, Hakonarson H J Mol Diagn. 2017; 19(4):561-566.

PMID: 28502727 PMC: 5500823. DOI: 10.1016/j.jmoldx.2017.04.002.


Validation and optimization of the Ion Torrent S5 XL sequencer and Oncomine workflow for BRCA1 and BRCA2 genetic testing.

Shin S, Kim Y, Oh S, Yu N, Lee S, Choi J Oncotarget. 2017; 8(21):34858-34866.

PMID: 28422718 PMC: 5471017. DOI: 10.18632/oncotarget.16799.


Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing.

Lin M, Mosier S, Thiess M, Beierl K, Debeljak M, Tseng L Am J Clin Pathol. 2014; 141(6):856-66.

PMID: 24838331 PMC: 4332779. DOI: 10.1309/AJCPMWGWGO34EGOD.